Gilead Sciences (NASDAQ:GILD) Given New $75.00 Price Target at UBS Group

Gilead Sciences (NASDAQ:GILD) had its price target decreased by UBS Group from $81.00 to $75.00 in a report issued on Wednesday, Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Oppenheimer lowered their price objective on Gilead Sciences from $115.00 to $105.00 and set an outperform rating for the company in a research report on Monday, February 12th. Truist Financial cut Gilead Sciences from a buy rating to a hold rating and cut their target price for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research report on Monday, March 4th. StockNews.com raised Gilead Sciences from a buy rating to a strong-buy rating in a report on Tuesday, March 26th. Finally, Mizuho lowered their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a buy rating on the stock in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of Hold and an average target price of $84.71.

Gilead Sciences Trading Down 0.6 %

Shares of GILD stock opened at $66.93 on Wednesday. The firm has a market capitalization of $83.33 billion, a P/E ratio of 14.87, a P/E/G ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock’s fifty day simple moving average is $72.25 and its 200 day simple moving average is $76.66. Gilead Sciences has a twelve month low of $66.89 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the prior year, the business earned $1.67 earnings per share. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GILD. Altshuler Shaham Ltd increased its position in shares of Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 121 shares during the period. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its position in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares in the last quarter. Financial Counselors Inc. increased its holdings in shares of Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 128 shares in the last quarter. Finally, Revolve Wealth Partners LLC increased its stake in Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.